Using the patient’s own immune system shows real promise in treating cancer. Genentech and BioNTech are longtime players in this field. The time to create the approach is shortening and other producers are entering the field.
Query: if each treatment is individualized, will pharma be able to create one big, blockbuster drug? Or will they have to rely on multiple treatments that are harder to replicate?
Regardless, any forward movement in the treatment of the emperor of maladies is good news indeed.
Stay tuned. Our next article will be about the burgeoning internet of things, privacy in that space, and the impact of blockchain in protecting the internet of things.
